Nasdaq:US$17.54 (-0.39) | HKEX:HK$26.68 (-1.00) | AIM:£2.50 (-0.1)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer